Clinical Trial Update: A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating anifrolumab targeting Type I IFN receptor in rheumatoid arthritis patients with high IFN signature.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: Josef Smolen, Univ. Prof. Dr. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: UNKNOWN